knowledge -WSS

knowledge

author：fashion 2025-09-03 15:16:39 - browse：7

What difference does a day make? Who gets to have gene therapy? And are biotech startups OK?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Jason Mast joins us to explain how the approval of a landmark gene therapy for Duchenne muscular dystrophy set in motion a frantic race to get children treated before their 6th birthdays. Then, HSBC Managing Director Jonathan Norris calls in to discuss why so many biotech startups are facing financial bridges to nowhere.

For more on what we cover, here’s the story on gene therapy; here’s more on Ipsen’s treatment for FOP; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Abortion pill case raises question: who can sue the FDA?

hotspot

WSS

A solution to the after

Alabama IVF ruling threatens families facing fatal genetic disease

Oprah kicked off a national conversation on obesity. Let's have it

Steward Health Care has deal to sell doctor network to UnitedHealth

Alabama frozen embryo ruling has major implications for IVF clinics

States should stop sabotaging methadone treatment reform

hotspot

knowledge

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Psychedelics group wrestles with new pharma identity

A new nitrogen execution bill also undermines medical licensing

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

State Dept. review finds Biden bears some blame for Afghanistan failures

Ed Silverman on new gene therapies, biosimilars, coffee, and more

State Dept. review finds Biden bears some blame for Afghanistan failures

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

focus

Abortion pill case raises question: who can sue the FDA?

Study says nonprofit hospitals fall short in charity care spending

A new nitrogen execution bill also undermines medical licensing

Ed Silverman on new gene therapies, biosimilars, coffee, and more

R1 RCM gets $5.8 billion buyout offer from private equity firm

Ed Silverman on new gene therapies, biosimilars, coffee, and more

knowledge

hotspot

knowledge

explore